- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03564080
Assessing the Feasibility of Including Patients With Peripheral Artery Disease in to an Established Cardiac Rehabilitation Service.
An Investigation Into the Feasibility of Incorporating an Exercise Rehabilitation Programme for People With Peripheral Artery Disease Into an Already Established Cardiac Rehabilitation Service.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Manchester
-
Salford, Manchester, United Kingdom, M6 8HD
- Salford Royal NHS Foundation Trust
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- General criteria As part of this study participants will be required to wear an accelerometer on the first week and last week of the 12 week study. The accelerometer will be kept in place by a medical dressing (e.g. Tegederm). People with an existing skin condition such as psoriasis or eczema that would be affected by the application of a medical dressing will be excluded from the study.
All participants must be able to start the incremental shuttle walk test (walking speed of 1.8kph, 1.1 mph).
All participants must be able to engage in the exercises prescribed in the programme
Inclusion Criteria - PAD patients:
All patients recruited will have had a recent diagnosis (0 - 12 months) of PAD made by either a vascular surgeon, vascular specialist nurse or specialist podiatrist.
Inclusion Criteria - CAD patients:
All patients recruited to the CR group will have had a recent diagnosis (0-12 months) of CAD (angina, myocardial infarction (MI), or coronary artery bypass graft (CABG) or valve surgery).
Exclusion Criteria:
- Exclusion criteria - PAD patients:
Any patient who has had previous intervention for PAD e.g. balloon angioplasty, stent, bypass or medication, or who have previously completed an SEP will be excluded from the study. This is due to the possibility of previous interventions having an impact on patient perceptions.
Participants who are on medication for PAD (e.g. naftidrofuryl oxalate) will also be excluded from the study as this can increase symptom management and improve functional capacity.
Any PAD patient who also has a diagnosis of other cardiovascular conditions such as CAD or stroke, or chronic heart failure will be excluded from this study, as the investigation is looking at the specific improvements in PAD, not CAD gains.
Exclusion criteria - CAD patients:
Any patient who has had previous diagnosis of PAD will be excluded from the study, as this may mask any gains in improvement due to CAD-specific rehabilitation in the CAD group (Tam et al., 2016).
Any participant who has unstable CAD (e.g. unstable angina) will be excluded from the study as this is a contraindication partaking in structured exercise programme (BACPR, 2012).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Control - PAD
This group of patients will complete the 'standard care' of supervised exercise as recommended by NICE.
|
|
Experimental: Combined - PAD and CAD
This group of PAD patients will exercise alongside CAD patients in an established supervised exercise programme (Cardiac Rehabilitation).
|
12-week supervised exercise programme in a hospital setting
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Walking distance
Time Frame: 12 weeks
|
Initial and maximal pain free walking distances are measured using a Incremental Shuttle Walk Test.
The symptoms of claudication pain are identified using the American Association of Cardiovascular and Pulmonary Rehabilitation (AACVPR) 0-4 Claudication scale.
0 is no claudication; 1 is initial pain; 2 is moderate pain; 3 is severe; 4 is maximal pain.
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Walking Impairment Questionnaire
Time Frame: 12 weeks
|
Patient's perceived walking distance and speed related to their claudication pain.
Participants rate the distance and speed they are able to walk at.
The distances are separated in to the amounts of blocks they can walk (with and without impairment).
They then rate the speed they can walk 100 yards.
The lower the score the worse the perceived limitation of their claudication symptoms.
|
12 weeks
|
King's College Vascular Quality of Life Questionnaire (VascQual)
Time Frame: 12 weeks
|
Disease-specific quality of life questionnaire.
The questionnaire is 25-item questionnaire subdivided into five domains: pain (4 items), symptoms (4 items), activities (8 items), social (2 items), and emotional (7 items).
The higher the score the lower the health-related quality of life.
|
12 weeks
|
Free-living physical activity levels
Time Frame: 12 weeks
|
Accelerometer data recording activity levels outside of rehabilitation programme
|
12 weeks
|
Hospital Anxiety and Depression Scale
Time Frame: 12 weeks
|
The is a generic quality of life questions that assesses levels of anxiety and depression.
There are 14 questions questions in total, 7 questions on anxiety and 7 on depression.
Each question has an answer rating from 0-3, with 0 being no evidence of anxiety/depression, and 3 being maximum score.
The total score for anxiety and depression are added (but anxiety and depression scores are not combined) to see the total reading for anxiety and depression.
If 11 or above is scored in either anxiety or depression, then referral to appropriate health care professional is discussed with participant.
|
12 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HSR1617-184
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cardiovascular Diseases
-
Medical College of WisconsinRecruitingCardiovascular Diseases | Cardiovascular Risk Factor | Cardiovascular HealthUnited States
-
Hospital Mutua de TerrassaCompleted
-
Oregon Health and Science UniversityCompletedCardiovascular Disease | Cardiovascular Risk FactorsUnited States
-
Women's College HospitalUniversity Health Network, Toronto; Sunnybrook Health Sciences Centre; Brigham... and other collaboratorsUnknownCARDIOVASCULAR DISEASESCanada, United States
-
Groupe Hospitalier Paris Saint JosephTerminatedCARDIOVASCULAR DISEASESFrance
-
University of FloridaUniversity of Alabama at Birmingham; Brown UniversityCompletedCardiovascular Disease | Psychosocial Influence on Cardiovascular DiseaseUnited States
-
VA Office of Research and DevelopmentNot yet recruitingCardiovascular DiseaseUnited States
-
Baptist Health South FloridaUniversity of California, Los Angeles; Quest Diagnostics-Nichols InsituteActive, not recruitingCardiovascular DiseaseUnited States
-
Laval UniversityActive, not recruitingCardiovascular DiseaseCanada
-
Penn State UniversityCalifornia Healthcare InstituteCompleted
Clinical Trials on Combined - PAD and CAD
-
Janssen Scientific Affairs, LLCHCA Research Institute, LLCRecruitingCoronary Artery Disease (CAD) | Peripheral Artery Disease (PAD)United States
-
University of Cape TownRadboud University Medical Center; University of Stellenbosch; Foundation for... and other collaboratorsRecruitingHIV Infections | COVID-19 | TuberculosisSouth Africa, Zambia, Zimbabwe
-
Koç UniversityNot yet recruitingQuality of Life | Incontinence, Urge | Incontinence Stress
-
National Taiwan University Hospital Hsin-Chu BranchUnknownSepsis | Peripheral Artery Disease | Diagnosis | Peripheral Artery OcclusionTaiwan
-
Instituto Ecuatoriano de Enfermedades DigestivasRecruitingColorectal Neoplasms | Colorectal DysplasiaEcuador
-
Ain Shams UniversityNot yet recruiting
-
Medipol UniversityCompletedCAD Test; Children's Vision; Colour Assessment; Colour Vision; TurkeyTurkey
-
CardioDxCompletedCardiovascular Diseases | Coronary Artery Disease | Chest Pain | Angina Pectoris | Coronary Heart Disease | CAD | CHD | CVD
-
National Institute on Aging (NIA)Completed
-
EndoVigilant IncCompletedAdenomatous Polyps | Polyp of Colon | Colo-rectal CancerUnited States